Someday, treating patients with nanorobots could become standard practice to deliver medicine specifically to parts of the body affected by disease. But merely injecting drug-loaded nanoparticles might not always be enough to get them where they need to go. Now scientists are reporting in the ACS journal Nano Letters the development of new nanoswimmers that can move easily through body fluids to their targets.
Stem cell-based therapies have the potential to transform the treatment of almost every major health condition, but possibly none quite as prevalent as heart disease. As the world’s number one cause of death, heart disease kills more than 7.5 million people each year, and its irreversible course leaves millions more dependent on devices and medications to survive.
Scientists from the Trinity College Dublin and the ITMO University have demonstrated that ordinary nanocrystals have intrinsic chirality, and this occurs due to chiral defects that take place naturally during normal nanocrystal synthesis. They have shown that the chiral nanocrystals could be produced as a half-and-half mixture under normal conditions and these would be mirror images of one another. This finding in nanocrystals has opened new possibilities in medicine, bio-technology and nanobiotechnology. In medicine it could be used for targeted delivery of drugs.
Chemists at Tufts University’s School of Arts and Sciences, collaborating with PerkinElmer and UCL (University College London), have witnessed atoms of one chemical element morph into another for the first time ever—a feat that produced an unexpected outcome that could lead to a new way to safely treat cancer with radiation.
Malvern Panalytical has launched a new system based around Taylor Dispersion Analysis (TDA) to provide researchers with a novel orthogonal technique to accelerate biopharmaceutical drug candidates through the development pipeline.
A U.S. patent has been awarded to a Kansas State University technology that quickly detects the early stages of cancer before physical symptoms ever appear.
Small heat shock proteins ensure that other proteins do not clot, allowing the cell to survive stress. Defects in these "small helpers" are associated with medical conditions like cataracts and cancer. Now, scientists at the Technische Universität München (TUM) have characterized a small heat shock protein responsible for embryonic development in the Caenorhabditis elegans nematode. Presumably, a similar protein exists also in humans.
Lehigh University engineers, materials scientists and chemists will present their innovative breakthroughs to a national showcase of investors and industrial partners at the TechConnect 2015 World Innovation Conference and National Innovation Showcase in Washington on June 14-17.
Ovarian cancer shuts down immune system cells that would otherwise act as a first line of defense against the deadly tumor, Weill Cornell Medical College scientists report today. But a therapy that restores the cells' disease-fighting abilities could provide a powerful new strategy to attack the cancer, which kills more than 14,000 women each year.
BIND Therapeutics, Inc., a clinical-stage nanomedicine company developing targeted and programmable therapeutics called Accurins™, and Macrophage Therapeutics, a subsidiary of Navidea Biopharmaceuticals, Inc. today announced they have entered into a research collaboration to engineer Accurins with the Manocept™ targeting platform that enables selective, efficient binding to CD206 positive disease-associated macrophages.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.